Effects of phlebotomy on the growth of ferric nitrilotriacetate-induced renal cell carcinoma. 2002

Akiko Mizote, and Akira I Hida, and Mutsumi Hosako, and Masayoshi Fujisawa, and Mika Kamekawa, and Shigeru Okada
Department of Pathological Research, Faculty of Medicine, Okayama University Graduate School of Medicine and Dentistry, Japan.

The ferric nitrilotriacetate-induced carcinogenesis model is unique in that reactive oxygen species-free radicals are involved in the carcinogenic process. But the effects of iron-withdrawal in the progression of renal cell carcinoma are not well understood. We performed repeated phlebotomies on animals that had been administered ferric nitrilotriacetate in the initiation stage of renal cell carcinoma (phlebotomy group), and compared the development of renal tumors with those not receiving repeated phlebotomies (non-phlebotomy group). Ferric nitrilotriacetate-treated male Wistar rats were randomly divided into 2 groups: a phlebotomy group (21 rats) and a non-phlebotomy group (17 rats). Ten age-adjusted normal rats were also observed as a normal group. Hematocrit was maintained under 25% in the phlebotomy group. Hematocrit levels in the normal group and in the non-phlebotomy group were not significantly different. As a result, the incidence of renal cell carcinoma was not significantly different between phlebotomy and non-phlebotomy animals. However, the total weight of the renal cell carcinoma was significantly heavier in the animals from non-phlebotomy group than in those from the phlebotomy group (23.64 g +/- 18.54 vs. 54.40 g +/- 42.40, P < 0.05). The present study demonstrated that phlebotomy after the administration of ferric nitrilotriacetate did not reduce the incidence of renal cell carcinoma. In addition, we showed that iron withdrawal at the promotion stage of carcinogenesis will retard tumor growth.

UI MeSH Term Description Entries
D007501 Iron A metallic element with atomic symbol Fe, atomic number 26, and atomic weight 55.85. It is an essential constituent of HEMOGLOBINS; CYTOCHROMES; and IRON-BINDING PROTEINS. It plays a role in cellular redox reactions and in the transport of OXYGEN. Iron-56,Iron 56
D007680 Kidney Neoplasms Tumors or cancers of the KIDNEY. Cancer of Kidney,Kidney Cancer,Renal Cancer,Cancer of the Kidney,Neoplasms, Kidney,Renal Neoplasms,Cancer, Kidney,Cancer, Renal,Cancers, Kidney,Cancers, Renal,Kidney Cancers,Kidney Neoplasm,Neoplasm, Kidney,Neoplasm, Renal,Neoplasms, Renal,Renal Cancers,Renal Neoplasm
D008297 Male Males
D009571 Nitrilotriacetic Acid A derivative of acetic acid, N(CH2COOH)3. It is a complexing (sequestering) agent that forms stable complexes with Zn2+. (From Miall's Dictionary of Chemistry, 5th ed.) Aluminum Nitrilotriacetate,Dysprosium Nitrilotriacetate,Trisodium Nitrilotriacetate,Acid, Nitrilotriacetic,Nitrilotriacetate, Aluminum,Nitrilotriacetate, Dysprosium,Nitrilotriacetate, Trisodium
D002273 Carcinogens Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included. Carcinogen,Oncogen,Oncogens,Tumor Initiator,Tumor Initiators,Tumor Promoter,Tumor Promoters,Initiator, Tumor,Initiators, Tumor,Promoter, Tumor,Promoters, Tumor
D002292 Carcinoma, Renal Cell A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma. Adenocarcinoma, Renal Cell,Carcinoma, Hypernephroid,Grawitz Tumor,Hypernephroma,Renal Carcinoma,Adenocarcinoma Of Kidney,Adenocarcinoma, Renal,Chromophil Renal Cell Carcinoma,Chromophobe Renal Cell Carcinoma,Clear Cell Renal Carcinoma,Clear Cell Renal Cell Carcinoma,Collecting Duct Carcinoma,Collecting Duct Carcinoma (Kidney),Collecting Duct Carcinoma of the Kidney,Nephroid Carcinoma,Papillary Renal Cell Carcinoma,Renal Cell Cancer,Renal Cell Carcinoma,Renal Cell Carcinoma, Papillary,Renal Collecting Duct Carcinoma,Sarcomatoid Renal Cell Carcinoma,Adenocarcinoma Of Kidneys,Adenocarcinomas, Renal Cell,Cancer, Renal Cell,Carcinoma, Collecting Duct,Carcinoma, Collecting Duct (Kidney),Carcinoma, Nephroid,Carcinoma, Renal,Carcinomas, Collecting Duct,Carcinomas, Collecting Duct (Kidney),Carcinomas, Renal Cell,Collecting Duct Carcinomas,Collecting Duct Carcinomas (Kidney),Hypernephroid Carcinoma,Hypernephroid Carcinomas,Hypernephromas,Kidney, Adenocarcinoma Of,Nephroid Carcinomas,Renal Adenocarcinoma,Renal Adenocarcinomas,Renal Carcinomas,Renal Cell Adenocarcinoma,Renal Cell Adenocarcinomas,Renal Cell Cancers,Renal Cell Carcinomas,Tumor, Grawitz
D005290 Ferric Compounds Inorganic or organic compounds containing trivalent iron. Compounds, Ferric
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D015994 Incidence The number of new cases of a given disease during a given period in a specified population. It also is used for the rate at which new events occur in a defined population. It is differentiated from PREVALENCE, which refers to all cases in the population at a given time. Attack Rate,Cumulative Incidence,Incidence Proportion,Incidence Rate,Person-time Rate,Secondary Attack Rate,Attack Rate, Secondary,Attack Rates,Cumulative Incidences,Incidence Proportions,Incidence Rates,Incidence, Cumulative,Incidences,Person time Rate,Person-time Rates,Proportion, Incidence,Rate, Attack,Rate, Incidence,Rate, Person-time,Rate, Secondary Attack,Secondary Attack Rates
D017208 Rats, Wistar A strain of albino rat developed at the Wistar Institute that has spread widely at other institutions. This has markedly diluted the original strain. Wistar Rat,Rat, Wistar,Wistar Rats

Related Publications

Akiko Mizote, and Akira I Hida, and Mutsumi Hosako, and Masayoshi Fujisawa, and Mika Kamekawa, and Shigeru Okada
April 2009, Basic & clinical pharmacology & toxicology,
Akiko Mizote, and Akira I Hida, and Mutsumi Hosako, and Masayoshi Fujisawa, and Mika Kamekawa, and Shigeru Okada
April 1987, Cancer research,
Akiko Mizote, and Akira I Hida, and Mutsumi Hosako, and Masayoshi Fujisawa, and Mika Kamekawa, and Shigeru Okada
November 1995, Japanese journal of cancer research : Gann,
Akiko Mizote, and Akira I Hida, and Mutsumi Hosako, and Masayoshi Fujisawa, and Mika Kamekawa, and Shigeru Okada
July 2017, Journal of clinical biochemistry and nutrition,
Akiko Mizote, and Akira I Hida, and Mutsumi Hosako, and Masayoshi Fujisawa, and Mika Kamekawa, and Shigeru Okada
September 2012, Journal of clinical biochemistry and nutrition,
Akiko Mizote, and Akira I Hida, and Mutsumi Hosako, and Masayoshi Fujisawa, and Mika Kamekawa, and Shigeru Okada
February 1985, Toxicology and applied pharmacology,
Akiko Mizote, and Akira I Hida, and Mutsumi Hosako, and Masayoshi Fujisawa, and Mika Kamekawa, and Shigeru Okada
July 2011, Environmental health and preventive medicine,
Akiko Mizote, and Akira I Hida, and Mutsumi Hosako, and Masayoshi Fujisawa, and Mika Kamekawa, and Shigeru Okada
June 1991, Cancer letters,
Akiko Mizote, and Akira I Hida, and Mutsumi Hosako, and Masayoshi Fujisawa, and Mika Kamekawa, and Shigeru Okada
September 2003, Toxicology,
Akiko Mizote, and Akira I Hida, and Mutsumi Hosako, and Masayoshi Fujisawa, and Mika Kamekawa, and Shigeru Okada
May 2004, Drug and chemical toxicology,
Copied contents to your clipboard!